Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trial Registries Would Boost Public Trust In Clinical Studies – Survey

This article was originally published in The Pink Sheet Daily

Executive Summary

Two-thirds of Americans queried in a December 2004 survey believe clinical trials are safe for participants, the Center for Information & Study on Clinical Research Participation reports. More than half of respondents said a public database of clinical trial results would boost their trust in such studies.

You may also be interested in...



Heart Concerns Shift To Aleve Following Alzheimer’s Trial

Preliminary data suggest long-term naproxen use caused a 50% increase in cardiovascular adverse events compared to placebo in a prematurely halted trial, which also included Pfizer's COX-2 inhibitor Celebrex (celecoxib)

Medical Journals To Require Registration Of All Controlled Trials On ClinicalTrials.gov

The International Committee of Medical Journal Editors will require that studies be registered at or before patient enrollment in order to be considered for publication. A Sept. 9 editorial notes that only ClinicalTrials.gov currently fits ICMJE registry criteria.

HHS Should Track All Rx Clinical Trials, AMA Says

All trials should be registered to ensure results are publicly available, physicians’ association says. Institutional review boards should not approve trials unless they are registered, AMA policy urges.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel